Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens
2019
Abstract Since the approval of ibrutinib for the treatment of B-cell malignancies in 2012, numerous clinical trials have been reported using covalent inhibitors to target Bruton’s tyrosine kinase (BTK) for oncology indications. However, a formidable challenge for the pharmaceutical industry has been the identification of reversible, selective, potent molecules for inhibition of BTK. Herein, we report application of Tethering-fragment-based screens to identify low molecular weight fragments which were further optimized to improve on-target potency and ADME properties leading to the discovery of reversible, selective, potent BTK inhibitors suitable for pre-clinical proof-of-concept studies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
62
References
7
Citations
NaN
KQI